-
results of a
Phase I-II
clinical trial that
CVnCoV (active
ingredient zorecimeran) was well-tolerated, safe, and
produced a
robust immune response. In...
-
collaboration for its COVID-19 vaccine,
named CVnCoV (active
ingredient zorecimeran), with the
multinational pharmaceutical company Bayer. As of December...
-
cooperation of BioNTech/Pfizer (BNT162b2), and by
Moderna (mRNA-1273). The
zorecimeran vaccine developed by Curevac, however, uses
unmodified mRNA, instead...
- of
Oxford (AZD1222),
Clover Biopharmaceuticals (SCB-2019),
CureVac (
Zorecimeran/CVnCoV),
Inovio (INO-4800),
Institut Pasteur (MV-SARS-CoV-2), Moderna...
